Latest Insider Transactions at Senti Biosciences, Inc. (SNTI)
This section provides a real-time view of insider transactions for Senti Biosciences, Inc. (SNTI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Senti Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Senti Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2024
|
Deborah Knobelman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,000
+43.53%
|
-
|
|
Feb 01
2024
|
K Lu Timothy CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
306,000
+26.12%
|
-
|
|
Feb 01
2024
|
Kanya Rajangam Pres. & Chief Med. & Dev. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
101,000
+50.0%
|
-
|
|
Oct 03
2022
|
Deborah Knobelman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Jun 08
2022
|
Dynamics Sponsor LLC Director |
SELL
Other acquisition or disposition
|
Direct |
6,465,500
-100.0%
|
-
|
|
Jun 08
2022
|
Dynamics Sponsor LLC Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750,000
+47.07%
|
-
|
|
Jun 08
2022
|
Omid Farokhzad Director |
BUY
Grant, award, or other acquisition
|
Indirect |
250,000
+50.0%
|
$2,500,000
$10.0 P/Share
|
|
Jun 08
2022
|
Omid Farokhzad Director |
SELL
Other acquisition or disposition
|
Indirect |
4,518,097
-69.88%
|
-
|
|
Jun 08
2022
|
Omid Farokhzad Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
5,750,000
+47.07%
|
-
|
|
Jun 08
2022
|
David R Epstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
112,519
+47.72%
|
-
|